HIGH YIELD | HIGH PURITY | HIGH ACTIVITY
Introducing the CL-7 affinity tag system.
Proteins play a central role in biotech and pharmaceutical research. As many as 80 percent of all drugs in development are either based on select proteins or act on proteins. More than a thousand drug candidates remain unexplored due to protein-related problems, with as many as a third of all membrane proteins having not been isolated at all.
That is why TriAltus Bioscience is working to transform protein-based research, making it easier and more affordable to obtain high-quality materials needed in the lab.
We believe researchers want to spend more time making discoveries in the search for new therapeutics, and less time working to produce their target proteins in the purity and quantity needed. Learn more about how our CL-7 affinity tag purification system can help.
Media & Scientific Publications
Scientists at Hubei University in China successfully used the CL7/Im7 purification system licensed by TriAltus Bioscience to purify Cas9 and Cas12a CRISPR-associated-proteins from E.coli in a single step with a substantially better yield than that of the conventional, multi-step protocol. Read more.
Protein purification is a primary step and the basis for numerous biochemical and biomedical studies. It is particularly crucial for high-resolution structural analysis and industrial protein production, where it has to meet the high-yield, high-purity, and high-activity (HHH) requirement. However, the HHH purification of many proteins or protein complexes remains a difficult, target-dependent, and multistep […]
Read about the launch of TriAltus Bioscience in our first news story, courtesy of the Birmingham Business Journal.